XClinical and IDDI: The best of 2 worlds

The IWR/IVR system ID-netTM developed by IDDI now provides an interface to MARVIN, XClinical’s EDC system

XClinical GmbH, Munich, Germany – March 25, 2011 – XClinical, a European vendor of innovative software products for eClinical trials known for its innovative and user-friendly CDISC ODM-certified EDC software suite MARVIN, presents the web-based open interface of IDDI’s ID-netTM to XClinical’s EDC system MARVIN at the DIA Annual EuroMeeting in Geneva.

About ID-netTM

ID-netTM is an Interactive Web Response System (IWRS) for centralized randomization and treatment allocation developed by IDDI in 2000 and used for all its randomization trials. More than 150 studies with over 100,000 patients have been conducted with the system. ID-netTM supports all types of randomization schemes and includes various features, such as study drug tracking and inventory management as well as patient registration, code break and withdrawal. In 2008, IDDI decided to implement XClinical’s EDC system MARVIN for conducting EDC trials in parallel of ID-netTM for randomization and drug supply management.

Web-based open interface to MARVIN

In May 2010, both companies’ Managing Directors – Dr. Philippe Verplancke and Damien Tremolet – initiated the project to build up a web-based open interface between ID-netTM and MARVIN. “We really appreciated the initiative, as this partnership reflects XClinical’s business strategy,” states Dr. Philippe Verplancke, CEO of XClinical. “The integration with IDDI’s randomization suite is an excellent example of the benefits of effectively bundling competencies.” XClinical could thus extend its own randomization capabilities with sophisticated dynamic randomization schemes offered by IDDI.
In May 2010, a multi-disciplinary project team from both companies wrote the specification documents and jointly tested the software implementations. ”The open interfaces of MARVIN and ID-netTM will facilitate connection with third party systems. The immediate return ,though, will be a single front-end to site personnel for EDC and randomization”, says Damien Tremolet, CEO of IDDI. “Today, software products providing such interfaces gain more acceptance. Furthermore, we are convinced of the positive outcome this new strategic partnership will generate.“
For more information on the interface of ID-netTM to MARVIN, visit XClinical at booth No. 1220 at the DIA Annual EuroMeeting in Geneva, Switzerland, taking place from March 28 to 30.

Or contact IDDI and XClinical directly:

Your contact at IDDI:
Catherine Indekeu
Phone: +32 / (0)10 / 621557
E-mail: catherine.indekeu@iddi.com
www.iddi.com
Your contact at XClinical
Dr. Philippe Verplancke
Phone: +49 / (0)89 / 452277 – 5100
E-mail: philippe.verplancke@xclinical.com
www.xclinical.com

About IDDI
IDDI (International Drug Development Institute) provides biostatistical and eClinical services including data management and innovative information systems to the pharmaceutical and biotechnology sector. ID-netTM uses web-based and/or voice technologies to deploy applications anywhere in the world in accordance with the trial protocol requirements. IDDI is based in Louvain-la-Neuve, Belgium, with offices in Cambridge, MA and Houston, TX, USA. Its 24/7 support team covers all countries.

About XClinical
XClinical GmbH (www.xclinical.com), an innovative EDC-CDM system vendor based in Munich, Paris and Boston, USA, provides solutions for the electronic conduct of all types of clinical trials, post-marketing studies and registries.
XClinical develops and markets MARVIN, a CDISC ODM-certified online platform for Electronic Data Capture (EDC), Clinical Data Management (CDM) and Clinical Trial Management (CTM).

Katharina Lang, XClinical GmbH, Phone: +49 (0)89 / 45 22 77 – 52 20
E-mail: press@xclinical.com

XClinical GmbH
Siegfriedstrasse 8
80803 Munich / Germany

Katharina Lang
kl@xclinical.com

This release was published on openPR.